Category Archives: Covid-19/2019-nCoV Dr. Lucey Q&A

COVID-19: South African variant may be worse than UK variant

By on .

A template is needed for the variants to come By Daniel R. Lucey M.D., MPH, FIDSA Overshadowed by reporting about the UK variant virus “B.1.1.7,”  a separate but similar variant SARS-CoV-2 virus in South Africa “501.V2” is under appreciated and deserves more international attention. Both variant viruses containing multiple mutations in the spike (S) protein, […]

COVID-19: UK virus may be more contagious, triggers European travel bans

By on .

Impact on vaccines and monoclonals remains unknown By Daniel R. Lucey M.D., MPH, FIDSA Today at least 10 European nations announced some new travel restrictions with regard to the United Kingdom due to a SARS-CoV-2 mutated variant that UK officials announced could be 70% more transmissible. See details below in two publications posted today including […]

COVID-19: Sweden advises new restrictions and masks on public transport

By on .

The King says “I think we have failed” By Daniel R. Lucey M.D., MPH, FIDSA As new COVID-19 illnesses, hospitalizations, ICU admissions, and deaths rise in Sweden, today the government posted new restrictions including for the first time use of face masks on public transport. This action follows the Dec.15 release of a 318-page interim […]

Five questions on new data from China-WHO showing 124 confirmed coronavirus patients in December 2019

By on .

By Daniel R. Lucey M.D., MPH, FIDSA After China initially reported 41, then ~ 46, and then ~ 100 laboratory-confirmed cases in December 2019, a total of 124 confirmed cases in December was reported by China July 31 but for some reason only posted on the WHO website Nov. 5. First posted on the WHO […]

COVID-19: Data on health care worker infections, deaths from 37 countries highlight PPE, training, protocol gaps

By on .

Authors call on WHO to track, post nation-by-nation numbers showing impacts on health personnel A paper published today in the International Journal of Infectious Diseases provides information for the first time on the toll of COVID-19 on health care workforces across 37 countries. The data, from the Americas, Asia, Europe, Africa and Middle Eastern nations […]

COVID-19: WHO-China team “Terms of Reference” reveal new data on seafood market

By on .

By Daniel R. Lucey M.D., MPH, FIDSA On Nov. 5, the World Health Organization posted on its website an important nine-page document titled: “WHO-Convened Global Study of the Origins of SARS-CoV2: Terms of Reference for the China Part.” This document is important for many reasons.  First, it is dated 31 July 2020 (upper left under […]

Pfizer/BioNTech COVID-19 vaccine efficacy: Six key questions

By on .

By Daniel R. Lucey M.D., MPH, FIDSA The Pfizer/BioNTech announcement today on findings from their first interim analysis of its Phase 3 COVID-19 vaccine candidate study showing 90% efficacy among 94 cases included the following excerpts, with key data pending: “Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned […]

COVID-19: With high tide waves across America, a request to the National Academy of Medicine on masks

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Today the Washington Post reported the United States had recorded the highest number of new cases (104,004) in one day, the highest number of hospitalizations in 18 states and 1,114 more deaths. In my opinion, the National Academy of Medicine should convene this month to provide a public […]

COVID-19: When will FDA convene an independent advisory committee for monoclonal antibody EUAs?  

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Rapidly evolving events regarding studies of monoclonal antibodies reemphasize the call first made here Oct. 19  that the U.S. Food and Drug Administration convene an outside expert advisory committee ASAP to advise on requests for Emergency Use Authorization for monoclonal antibodies against SARS-CoV-2. On Oct. 7 Lilly announced […]

Will the Oct. 22 FDA COVID-19 vaccine EUA meeting discuss the statistical basis for requiring at least five severe cases in placebo group of Phase 3 vaccine studies? 

By on .

By Daniel R. Lucey M.D., MPH, FIDSA In reference to potential enhanced respiratory disease associated with COVID-19 vaccine candidates, the U.S. Food and Drug Administration briefing document for the Oct. 22 public advisory committee meeting on COVID-19 Vaccine Emergency Use Authorization states (on p. 11 of Appendix II): “Sufficient cases of severe COVID-19 among study […]